INCB047986

DRUG3 trials

Sponsors

Incyte Corporation

Conditions

Advanced CancerBreast CancerHodgkin's LymphomaMDS (Myelodysplastic Syndrome)Metastatic CancerNHL (Non-Hodgkin Lymphoma)Pancreatic CancerRheumatoid Arthritis

Phase 1

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

TerminatedNCT01929941

Incyte CorporationAdvanced Cancer, Breast Cancer, Hodgkin's Lymphoma +5

Start: 2013-09-30End: 2014-08-31Updated: 2018-01-17

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

TerminatedNCT02093429

Incyte CorporationMDS (Myelodysplastic Syndrome)

Start: 2014-01-31End: 2014-09-30Updated: 2018-01-17

Phase 2

INCB047986 in Rheumatoid Arthritis

TerminatedNCT02151474

Incyte CorporationRheumatoid Arthritis

Start: 2014-05-31End: 2014-08-31Updated: 2015-02-23